Univercells Technologies, a Donaldson Life Sciences business, announced the launch of its scale-X™ nitro controller on May 7, 2025. This new controller is the latest addition to its scale-X fixed-bed bioreactor portfolio, designed to enhance bioprocessing capabilities.
The scale-X nitro controller is engineered to operate both the 200 and 600 m² scale-X nitro bioreactors. It offers a cost-effective, low-footprint, and user-friendly solution for large-scale viral and advanced therapy manufacturing, addressing key industry needs.
This product introduction reinforces Donaldson's strategic investments in the Life Sciences segment, particularly in bioprocessing. The technology aims to improve the efficiency and accessibility of manufacturing critical components for cell and gene therapies and viral vaccines.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.